Tag: patient

In a recent video Q&A, board-certified plastic surgeon Dr. Pane breaks down the differences between tummy tuck, revision surgery, and liposuction, helping patients choose...

As more women seek revision or removal of breast implants, Dr. Pane offers safe, personalized solutions with long-term, natural-looking results. NORTH PALM BEACH, Fla., Aug....

NEW ORLEANS, Aug. 8, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file...

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/...

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

ROSEMONT, Ill., Aug. 8, 2025 /PRNewswire/ -- (AANA) -- Wisconsin recently enacted legislation that allows more autonomy for Advanced Practice Registered Nurses (APRNs), including...

Nurse Practitioners, Physician Assistants, and Certified Nurse Midwives at Cape Cod Healthcare move to join the MNA for an equal voice in clinical decisions CAPE...

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update